CMTP Publishes Guidance for Assessing Utility and Validity of Cancer Molecular Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Seeking to set a standard for how molecular diagnostic cancer tests are evaluated, the Center for Medical Technology Policy has issued a set of recommendations covering how to best assess the clinical validity and utility of these tests.

While molecular diagnostic tests offer great promise for oncology, evidence supporting the use and safety of these tests is lacking, and there is "considerable debate" about how much evidence is required and how it should be acquired, CMTP said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.